Evidence-based management of chemotherapy-induced nausea and vomiting: A position statement from a European cancer nursing forum

ecancermedicalscience

Volumn 5, Issue 1, 2011, Pages

  Vidall, C ^a   Dielenseger, P ^b   Farrell, C ^c   Lennan, E ^d   Muxagata, P ^e   Fernandez Ortega P ^f   Paradies, K ^g  

^a Clinical Risk and Practice Development   (United Kingdom)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e Sousa Martins Hospital   (Portugal)

^f CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^g Gynaecological and Oncological Outpatient Clinic Prof Dr Schmidt Rohde   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; DEXAMETHASONE; HISTAMINE H2 RECEPTOR ANTAGONIST; LORAZEPAM; NEUROKININ 1 RECEPTOR ANTAGONIST; PALONOSETRON; PROTON PUMP INHIBITOR; SEROTONIN 3 ANTAGONIST;

ARTICLE; CHEMOTHERAPY INDUCED EMESIS; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; PRACTICE GUIDELINE; PROPHYLAXIS;

EID: 84857029590     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2011.211     Document Type: Article

References (10)

1. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting N Engl J Med 358 2482-94 PMID: 18525044
2. NCCN (2011) NCCN clinical practice guidelines in oncology, Antiemesis V.3.2011 http://www.nccn.org/professionals/physician-gls/pdf/antiemesis.pdf
3. Börjeson S, Hursti TJ, Tishelman C, Peterson C, Steineck G (2002) Treatment of nausea and emesis during cancer chemotherapy: discrepancies between antiemetic effect and well-being J Pain Symptom Manage 24 345-58 PMID: 12458116 (Pubitemid 35379717)
4. Glaus A, Knipping C, Morant R, Böhme C, Lebert B, Beldermann F, Glawogger B, Ortega PF, Hüsler A, Deuson R (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective Support Care Cancer 12 708-15 PMID: 15278682 (Pubitemid 39362649)
5. Bosly A. Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP Ann Hematol 87 277-83 PMID: 17952688 (Pubitemid 351445288)
6. Pettengell R, Schwenkglenks M, Bosly A (2008) Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy Ann Hematol 87 429-30 PMID: 18299833
7. Young A, Crowe M, Vidall C, Lennan E, Roe H, Sharp S, White T (2009) Delivery of chemotherapy at planned dose and on time Cancer Nurs Pract 8 16-19
8. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilia C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 901-6 PMID: 7877646
9. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 J Clin Oncol 24 2932-47 PMID: 16717289 (Pubitemid 46630595)
10. MASCC (2011) MASCC/ESMO antiemetic guideline 2011 http://data. memberclicks.com/site/mascc/MASCC-Guidelines-English-2011.pdf